Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

Aptose Biosciences Inc TSX: APS-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 3.25
Day High 3.42
Open:3.40
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. CG026806 (CG-806), its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL).

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
- GlobeNewswire - Tue Jul 20, 3:01PM CDT
GlobeNewswire - CMTX
Tue Jul 20, 3:01PM CDT
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market.
Aptose Presents Highlights from EHA During Corporate Update Event
- GlobeNewswire - Fri Jun 11, 6:55AM CDT
GlobeNewswire - CMTX
Fri Jun 11, 6:55AM CDT
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET, in concurrence with participation at the EHA2021 Virtual Congress (EHA). The event is focused on the current clinical status of luxeptinib, Aptose's oral, first-in-class FLT3 and BTK kinase inhibitor currently in two Phase 1 a/b trials, one trial in patients with relapsed or refractory acute myeloid leukemia (AML), and the other trial in patients with relapsed or refractory B cell malignancies. The live and archived webcast of the presentation is available on Aptose's website here.
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
- GlobeNewswire - Tue Jun 1, 4:43PM CDT
GlobeNewswire - CMTX
Tue Jun 1, 4:43PM CDT
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 1, 2021 (the "Meeting"). A total of 72.83% of the issued and outstanding common shares of the Company were represented by shareholders present or represented by proxy at the Meeting.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 3.21 +1.87% increase
on 07/27/21
Period Open:4.18
Price movement based on the high, low and last over the given period.
4.30 -23.95% decrease
on 07/05/21
-0.91 (-21.77%) decrease
since 06/29/21
3-Month 3.21 +1.87% increase
on 07/27/21
Period Open:6.90
Price movement based on the high, low and last over the given period.
7.14 -54.20% decrease
on 04/30/21
-3.63 (-52.61%) decrease
since 04/29/21
52-Week 3.21 +1.87% increase
on 07/27/21
Period Open:6.55
Price movement based on the high, low and last over the given period.
9.40 -65.21% decrease
on 12/01/20
-3.28 (-50.08%) decrease
since 07/29/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies